These findings not only provide a pharmacological basis for the therapeutic use of β-AR antagonists in the treatment of IH but also unveil a functional connection between the β-ARs and VEGFR-2 in HemECs. The gene discussed is KDR; the disease is isolated hemihyperplasia.